- BrightGene looks to the West as obesity shot nears China approvalArmed with impressive Phase 3 data, BrightGene is taking its obesity shot to Chinese regulators. It expects trial data in the West to be even stronger, but its search for a partner for ex-China ter…Endpoints · 24d ago↗ source
- STAT+: Halfway into the year, biotech is boomingThe biotech stock rally that began in April 2025 has not stopped, and if anything, has accelerated.STAT · 24d ago↗ source
- Opinion: Teens are turning to chatbots for mental health help. We need rules to keep them safeThe share of young people using AI chatbots for mental health advice rose more than 40% in a single year, researcher writes.STAT · 24d ago↗ source